United States Blood Plasma Derivatives Market with CAGR of 4.3% during 2022-2029 - Exclusive Report by DatamIntelligence

"The Global Blood Plasma Derivatives Market is predicted to reach at a high CAGR of 4.3% during the forecast period (2022-2029)" As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/blood-plasma-derivatives-market?sp

United States: Recent Industry Developments

✅ In October 2025, U.S. plasma collection centers expanded adoption of advanced automated donation systems, reducing collection times by approximately 30% and improving donor safety and comfort. This upgrade enhances plasma supply efficiency supporting growing demand for therapies. It reflects ongoing innovation in plasma fractionation technology.

✅ In September 2025, Grifols partnered with Inpeco to incorporate advanced robotics and automation in blood and plasma testing labs, creating high-throughput "labs of the future" with improved safety and traceability. This initiative aims to increase production capacity and diagnostic reliability in transfusion medicine.

✅ In August 2025, Kedrion Biopharma expanded its distribution network for Ryplazim, a plasma-derived plasminogen therapy for treating congenital plasminogen deficiency across the U.S. This expansion improves access to critical therapies for rare blood disorders, facilitating better patient outcomes.

✅ In June 2024, Biotest's Yimmugo, an intravenous immunoglobulin therapy, received FDA approval for treatment of primary antibody deficiency syndromes. This plasma protein therapy addresses immune system deficiencies, expanding treatment options for patients with compromised antibody function.

Japan: Recent Industry Developments

✅ In September 2025, Takeda Pharmaceuticals announced revisions to its large-scale plasma-derived therapies manufacturing facility project in Osaka, reaffirming commitment with increased investment to expand production capacity targeting 2029 completion. This facility supports supply stability for Japan and global markets.

✅ In May 2025, Nara Medical University commenced the world's first clinical trials of artificial blood using hemoglobin vesicles, aiming for clinical use by 2030. This innovation tackles blood shortages, with broad implications for plasma and blood derivative therapies in Japan.

✅ In February 2025, CSL Behring received Japanese regulatory approval for ANDEMBRY® (garadacimab) Subcutaneous Injection 200mg pens, a first-in-class monoclonal antibody for hereditary angioedema prevention with once-monthly administration. This strengthens Japan's plasma therapy portfolio.

✅ In March 2025, Japan's blood plasma derivative market was projected to grow strongly driven by an aging population and increased prevalence of chronic diseases. Innovations in plasma collection, fractionation, and product development improve therapy safety and efficacy, supported by favorable government policies and reimbursement frameworks.

Blood Plasma Derivatives Market: Drivers

The blood plasma derivatives market is growing steadily due to increasing demand for therapies addressing immune deficiencies, bleeding disorders, and critical care conditions. Products such as immunoglobulins, albumin, and clotting factors are essential in treating diseases like hemophilia, primary immunodeficiency, and shock. Advances in plasma fractionation and purification technologies are enhancing product safety, efficacy, and supply reliability. Rising awareness of rare and chronic disorders is driving adoption among hospitals, specialty clinics, and treatment centers. The expansion of healthcare infrastructure and improved access to life-saving therapies are further supporting market growth.

Increasing global demand for immunotherapy and critical care treatments is fueling the consumption of plasma-derived products. Technological innovations in pathogen reduction, recombinant alternatives, and storage stability are enhancing treatment outcomes and patient safety. Collaborations between plasma collection centers, biotech firms, and healthcare providers are improving supply chain efficiency. Government initiatives and regulatory frameworks promoting safe plasma collection and therapy availability are strengthening market credibility. With rising prevalence of chronic and immune-related disorders, the blood plasma derivatives market is poised for sustained growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/blood-plasma-derivatives-market?sp

Blood Plasma Derivatives Market: Major Players

Grifols, S.A., SK Plasma Co., Ltd., Fusion Health Care Pvt. Ltd., Biotest AG, Green Cross Corporation, Baxter International Inc., LFB S.A., Octapharma AG, CSL Limited and Shire Plc.

Segment Covered in the Blood Plasma Derivatives Market:

➥ By Type: Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others

➥ By Application: Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrand's Disease (vWD), Others

➥ By End-user: Hospitals, Clinics, Others

Research Process:

Both primary and secondary data sources have been used in the Blood Plasma Derivatives Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Blood Plasma Derivatives Market Research Industry:

➠ Who leads the Blood Plasma Derivatives industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Blood Plasma Derivatives market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Blood Plasma Derivatives market growth?
➠ What are the dominant sales and distribution strategies in the Blood Plasma Derivatives industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=blood-plasma-derivatives-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.